Hematopoietic Progenitor Kinase 1 in Tumor Immunology: A Medicinal Chemistry Perspective.

Abstract

Hematopoietic progenitor kinase 1 (HPK1), a hematopoietic cell-restricted member of the serine/threonine Ste20-related protein kinases, is a negative regulator of the T cell receptor, B cell receptor, and dendritic cells. Loss of HPK1 kinase function increases cytokine secretion and enhances T cell signaling, virus clearance, and tumor growth inhibition. Therefore, HPK1 is considered a promising target for tumor immunotherapy. Several HPK1 inhibitors have been reported to regulate T cell function. In addition, HPK1-targeting PROTACs, which can induce the degradation of HPK1, have also been developed. Here, we provide an overview of research concerning HPK1 protein structure, function, and inhibitors and propose perspectives and insights for the future development of agents targeting HPK1.

• Authors: Qiangsheng Zhu, Nannan Chen, Xinjian Tian, Yeling Zhou, QiDong You, Xiaoli Xu
• Journal: Journal of medicinal chemistry (J Med Chem) Vol. 65 Issue 12 Pg. 8065-8090 (06 23 2022) ISSN: 1520-4804 [Electronic] United States
• PMID: 35696642 (Publication Type: Journal Article, Review, Research Support, Non-U.S. Gov't)

Chemical References

• hematopoietic progenitor kinase 1
• Protein Serine-Threonine Kinases

Topics

• Chemistry, Pharmaceutical
• Humans
• Neoplasms (drug therapy)
• Protein Serine-Threonine Kinases
• Signal Transduction